English

Ascelia Pharma

ESEF

Report (type unavailable) · filed 2025-05-08

Annual consolidated revenue for 2024: about SEK 0, using the latest reported figures. The previous period, 2023, was about SEK 0.

Inspect reported changes Compare with another company Historical disclosures Segments

Watchlist

Latest fiscal year

Revenue

0 SEK

2024 · SEK

Exact inputs and evidence

Revenue: 0 SEK Source

Operating cash flow

-62.8 million SEK

2024 · SEK

Exact inputs and evidence

Operating Cash Flow: -62844000 SEK Source

Free cash flow

-62.8 million SEK

2024 · SEK

Exact inputs and evidence

Operating Cash Flow: -62844000 SEK Source
Capital Expenditure: 0 SEK Source

Cash and cash equivalents: 75.3 million SEK 2024-12-31 Source
Exact value

75256000 SEK
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2025-05-08.

Financial data available through: 2024-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2024-12-31
Operating income: 5 of 11 periods available· newest 2024-12-31
Net income: 5 of 11 periods available· newest 2024-12-31
Operating cash flow: 5 of 11 periods available· newest 2024-12-31
Capital expenditure: 5 of 11 periods available· newest 2024-12-31
Total assets: 5 of 11 periods available· newest 2024-12-31
Total liabilities: 5 of 11 periods available· newest 2024-12-31
Current assets: 5 of 11 periods available· newest 2024-12-31
Current liabilities: 5 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2024-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
SEK 0

Prior period

SEK 0

2023-01-01 – 2023-12-31
Current period

SEK 0

2024-01-01 – 2024-12-31

Exact inputs and evidence

0 − 0 = 0 SEK

0 SEK · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
0 SEK · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Ascelia Pharma · 2024-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Year-over-year change in Revenue: 0 SEK Concept: fundies:Revenue Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 SEK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2024-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2024-12-31-0-sv.zip#25758320 Filing: 5493002YR9VCJJPWYN08-2024-12-31-ESEF-SE-0 Input fundies:Revenue: 0 SEK (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2024-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2024-12-31-0-sv.zip#25758759 Filing: 5493002YR9VCJJPWYN08-2024-12-31-ESEF-SE-0
The citation records this snapshot. The page link may show a newer release later.
Net income
+SEK 29.26 million

Prior period

−SEK 109.29 million

2023-01-01 – 2023-12-31
Current period

−SEK 80.03 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-80029000 − -109288000 = 29259000 SEK

-109288000 SEK · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-80029000 SEK · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Ascelia Pharma · 2024-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Year-over-year change in Net income: 29259000 SEK Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -80029000 SEK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2024-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2024-12-31-0-sv.zip#25780741 Filing: 5493002YR9VCJJPWYN08-2024-12-31-ESEF-SE-0 Input fundies:NetIncome: -109288000 SEK (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2024-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2024-12-31-0-sv.zip#25781231 Filing: 5493002YR9VCJJPWYN08-2024-12-31-ESEF-SE-0
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+SEK 63.95 million

Prior period

−SEK 126.79 million

2023-01-01 – 2023-12-31
Current period

−SEK 62.84 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-62844000 − -126792000 = 63948000 SEK

-126792000 SEK · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-62844000 SEK · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Ascelia Pharma · 2024-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Year-over-year change in Operating cash flow: 63948000 SEK Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -62844000 SEK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2024-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2024-12-31-0-sv.zip#25993675 Filing: 5493002YR9VCJJPWYN08-2024-12-31-ESEF-SE-0 Input fundies:OperatingCashFlow: -126792000 SEK (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2024-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2024-12-31-0-sv.zip#25994165 Filing: 5493002YR9VCJJPWYN08-2024-12-31-ESEF-SE-0
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
SEK 0

Prior period

SEK 0

2023-01-01 – 2023-12-31
Current period

SEK 0

2024-01-01 – 2024-12-31

Exact inputs and evidence

0 − 0 = 0 SEK

0 SEK · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
0 SEK · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Ascelia Pharma · 2024-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Year-over-year change in Capital expenditure: 0 SEK Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 0 SEK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2024-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2024-12-31-0-sv.zip#25995870 Filing: 5493002YR9VCJJPWYN08-2024-12-31-ESEF-SE-0 Input fundies:CapitalExpenditure: 0 SEK (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2024-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2024-12-31-0-sv.zip#25996369 Filing: 5493002YR9VCJJPWYN08-2024-12-31-ESEF-SE-0
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2024-01-01 – 2024-12-31

Revenue SEK 0
Operating costs Derived SEK 67.77 million
Operating income −SEK 67.77 million
Tax, interest and other Derived SEK 12.26 million
Net income −SEK 80.03 million

Cash

Operating cash flow −SEK 62.84 million
Capital expenditure SEK 0
Free cash flow Derived −SEK 62.84 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.
2023 Not shown: operating income or net income is not reported.
2024 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	93428000 Derived	-93428000	5269000 Derived	-98697000	-85924000 Derived	Source 2020-01-01 – 2020-12-31: 0 SEK Inspect Revenue Open source 2020-01-01 – 2020-12-31: -93428000 SEK Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -98697000 SEK Inspect Net Income Open source 2020-01-01 – 2020-12-31: -85527000 SEK Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 397000 SEK Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	137948000 Derived	-137948000	-12045000 Derived	-125903000	-116597000 Derived	Source 2021-01-01 – 2021-12-31: 0 SEK Inspect Revenue Open source 2021-01-01 – 2021-12-31: -137948000 SEK Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -125903000 SEK Inspect Net Income Open source 2021-01-01 – 2021-12-31: -116559000 SEK Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 38000 SEK Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	147007000 Derived	-147007000	-15784000 Derived	-131223000	-125263000 Derived	Source 2022-01-01 – 2022-12-31: 0 SEK Inspect Revenue Open source 2022-01-01 – 2022-12-31: -147007000 SEK Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -131223000 SEK Inspect Net Income Open source 2022-01-01 – 2022-12-31: -125263000 SEK Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 0 SEK Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	110914000 Derived	-110914000	-1626000 Derived	-109288000	-126792000 Derived	Source 2023-01-01 – 2023-12-31: 0 SEK Inspect Revenue Open source 2023-01-01 – 2023-12-31: -110914000 SEK Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -109288000 SEK Inspect Net Income Open source 2023-01-01 – 2023-12-31: -126792000 SEK Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 0 SEK Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	67766000 Derived	-67766000	12263000 Derived	-80029000	-62844000 Derived	Source 2024-01-01 – 2024-12-31: 0 SEK Inspect Revenue Open source 2024-01-01 – 2024-12-31: -67766000 SEK Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -80029000 SEK Inspect Net Income Open source 2024-01-01 – 2024-12-31: -62844000 SEK Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 0 SEK Inspect Capital Expenditure Open source

Amounts are exact, in SEK.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

SEK 0 2024

Values and sources

Revenue values and source evidence
Period	Series	Source evidence
20202020-12-31	Revenue	Revenue: 0 Open source
20212021-12-31	Revenue	Revenue: 0 Open source
20222022-12-31	Revenue	Revenue: 0 Open source
20232023-12-31	Revenue	Revenue: 0 Open source
20242024-12-31	Revenue	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20222022-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20232023-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20242024-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	Not reported	Operating Income: -93428000 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	Not reported	Operating Income: -137948000 Open source Revenue: 0 Open source
20222022-12-31	Operating margin	Not reported	Operating Income: -147007000 Open source Revenue: 0 Open source
20232023-12-31	Operating margin	Not reported	Operating Income: -110914000 Open source Revenue: 0 Open source
20242024-12-31	Operating margin	Not reported	Operating Income: -67766000 Open source Revenue: 0 Open source
20202020-12-31	Net margin	Not reported	Net Income: -98697000 Open source Revenue: 0 Open source
20212021-12-31	Net margin	Not reported	Net Income: -125903000 Open source Revenue: 0 Open source
20222022-12-31	Net margin	Not reported	Net Income: -131223000 Open source Revenue: 0 Open source
20232023-12-31	Net margin	Not reported	Net Income: -109288000 Open source Revenue: 0 Open source
20242024-12-31	Net margin	Not reported	Net Income: -80029000 Open source Revenue: 0 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -85527000 Open source Capital Expenditure: 397000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -116559000 Open source Capital Expenditure: 38000 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -125263000 Open source Capital Expenditure: 0 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -126792000 Open source Capital Expenditure: 0 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -62844000 Open source Capital Expenditure: 0 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

SEK -62.8M 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(SEK)	Source evidence
20202020-12-31	Operating cash flow	-85527000	Operating Cash Flow: -85527000 Open source
20212021-12-31	Operating cash flow	-116559000	Operating Cash Flow: -116559000 Open source
20222022-12-31	Operating cash flow	-125263000	Operating Cash Flow: -125263000 Open source
20232023-12-31	Operating cash flow	-126792000	Operating Cash Flow: -126792000 Open source
20242024-12-31	Operating cash flow	-62844000	Operating Cash Flow: -62844000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

SEK -62.8M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(SEK)	Source evidence
20202020-12-31	Free cash flow	-85924000	Operating Cash Flow: -85527000 Open source Capital Expenditure: 397000 Open source
20212021-12-31	Free cash flow	-116597000	Operating Cash Flow: -116559000 Open source Capital Expenditure: 38000 Open source
20222022-12-31	Free cash flow	-125263000	Operating Cash Flow: -125263000 Open source Capital Expenditure: 0 Open source
20232023-12-31	Free cash flow	-126792000	Operating Cash Flow: -126792000 Open source Capital Expenditure: 0 Open source
20242024-12-31	Free cash flow	-62844000	Operating Cash Flow: -62844000 Open source Capital Expenditure: 0 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

44% 2024

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	7.6%	Total Liabilities: 19318000 Open source Total Assets: 255374000 Open source
20212021-12-31	Liabilities / assets	7.7%	Total Liabilities: 25659000 Open source Total Assets: 333493000 Open source
20222022-12-31	Liabilities / assets	17.3%	Total Liabilities: 37711000 Open source Total Assets: 218569000 Open source
20232023-12-31	Liabilities / assets	14.6%	Total Liabilities: 12744000 Open source Total Assets: 87072000 Open source
20242024-12-31	Liabilities / assets	44%	Total Liabilities: 61976000 Open source Total Assets: 140920000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.35× 2024

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	10.69×	Current Assets: 196324000 Open source Current Liabilities: 18362000 Open source
20212021-12-31	Current assets / current liabilities	10.94×	Current Assets: 274611000 Open source Current Liabilities: 25106000 Open source
20222022-12-31	Current assets / current liabilities	4.29×	Current Assets: 160869000 Open source Current Liabilities: 37518000 Open source
20232023-12-31	Current assets / current liabilities	2.3×	Current Assets: 28937000 Open source Current Liabilities: 12568000 Open source
20242024-12-31	Current assets / current liabilities	1.35×	Current Assets: 83718000 Open source Current Liabilities: 61976000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	−SEK 98.7 million Exact value Exact value: -98697000 SEK 2020-01-01 – 2020-12-31: -98697000 SEK Inspect Net Income Open source Share or cite Citation for Net Income · Ascelia Pharma · 2020-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Net Income: -98697000 SEK Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=SEK&dimensions= Input fundies:NetIncome: -98697000 SEK (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2021-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2021-12-31-sv.zip#20430253 Filing: 5493002YR9VCJJPWYN08-2021-12-31-ESEF-SE-0 The citation records this snapshot. The page link may show a newer release later.	−SEK 85.53 million Exact value Exact value: -85527000 SEK 2020-01-01 – 2020-12-31: -85527000 SEK Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Ascelia Pharma · 2020-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Operating Cash Flow: -85527000 SEK Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=SEK&dimensions= Input fundies:OperatingCashFlow: -85527000 SEK (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2021-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2021-12-31-sv.zip#20554781 Filing: 5493002YR9VCJJPWYN08-2021-12-31-ESEF-SE-0 The citation records this snapshot. The page link may show a newer release later.	SEK 397,000 Exact value Exact value: 397000 SEK 2020-01-01 – 2020-12-31: 397000 SEK Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Ascelia Pharma · 2020-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Capital Expenditure: 397000 SEK Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=SEK&dimensions= Input fundies:CapitalExpenditure: 397000 SEK (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2021-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2021-12-31-sv.zip#20555688 Filing: 5493002YR9VCJJPWYN08-2021-12-31-ESEF-SE-0 The citation records this snapshot. The page link may show a newer release later.	−SEK 85.92 million Calculation and evidence -85527000 − 397000 SEK Exact free cash flow: -85924000 SEK 2020-01-01 – 2020-12-31: -85527000 SEK · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 397000 SEK · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Ascelia Pharma · 2020-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Free cash flow: -85924000 SEK Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -85527000 SEK (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2021-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2021-12-31-sv.zip#20554781 Filing: 5493002YR9VCJJPWYN08-2021-12-31-ESEF-SE-0 Input fundies:CapitalExpenditure: 397000 SEK (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2021-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2021-12-31-sv.zip#20555688 Filing: 5493002YR9VCJJPWYN08-2021-12-31-ESEF-SE-0 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−SEK 125.9 million Exact value Exact value: -125903000 SEK 2021-01-01 – 2021-12-31: -125903000 SEK Inspect Net Income Open source Share or cite Citation for Net Income · Ascelia Pharma · 2021-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Net Income: -125903000 SEK Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=SEK&dimensions= Input fundies:NetIncome: -125903000 SEK (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2022-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2022-12-31-sv.zip#25262327 Filing: 5493002YR9VCJJPWYN08-2022-12-31-ESEF-SE-0 The citation records this snapshot. The page link may show a newer release later.	−SEK 116.56 million Exact value Exact value: -116559000 SEK 2021-01-01 – 2021-12-31: -116559000 SEK Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Ascelia Pharma · 2021-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Operating Cash Flow: -116559000 SEK Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=SEK&dimensions= Input fundies:OperatingCashFlow: -116559000 SEK (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2022-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2022-12-31-sv.zip#25376245 Filing: 5493002YR9VCJJPWYN08-2022-12-31-ESEF-SE-0 The citation records this snapshot. The page link may show a newer release later.	SEK 38,000 Exact value Exact value: 38000 SEK 2021-01-01 – 2021-12-31: 38000 SEK Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Ascelia Pharma · 2021-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Capital Expenditure: 38000 SEK Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=SEK&dimensions= Input fundies:CapitalExpenditure: 38000 SEK (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2022-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2022-12-31-sv.zip#25376983 Filing: 5493002YR9VCJJPWYN08-2022-12-31-ESEF-SE-0 The citation records this snapshot. The page link may show a newer release later.	−SEK 116.6 million Calculation and evidence -116559000 − 38000 SEK Exact free cash flow: -116597000 SEK 2021-01-01 – 2021-12-31: -116559000 SEK · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 38000 SEK · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Ascelia Pharma · 2021-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Free cash flow: -116597000 SEK Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -116559000 SEK (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2022-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2022-12-31-sv.zip#25376245 Filing: 5493002YR9VCJJPWYN08-2022-12-31-ESEF-SE-0 Input fundies:CapitalExpenditure: 38000 SEK (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2022-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2022-12-31-sv.zip#25376983 Filing: 5493002YR9VCJJPWYN08-2022-12-31-ESEF-SE-0 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−SEK 131.22 million Exact value Exact value: -131223000 SEK 2022-01-01 – 2022-12-31: -131223000 SEK Inspect Net Income Open source Share or cite Citation for Net Income · Ascelia Pharma · 2022-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Net Income: -131223000 SEK Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=SEK&dimensions= Input fundies:NetIncome: -131223000 SEK (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2023-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2023-12-31-sv.zip#36116618 Filing: 5493002YR9VCJJPWYN08-2023-12-31-ESEF-SE-0 The citation records this snapshot. The page link may show a newer release later.	−SEK 125.26 million Exact value Exact value: -125263000 SEK 2022-01-01 – 2022-12-31: -125263000 SEK Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Ascelia Pharma · 2022-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Operating Cash Flow: -125263000 SEK Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=SEK&dimensions= Input fundies:OperatingCashFlow: -125263000 SEK (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2023-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2023-12-31-sv.zip#36314411 Filing: 5493002YR9VCJJPWYN08-2023-12-31-ESEF-SE-0 The citation records this snapshot. The page link may show a newer release later.	SEK 0 Exact value Exact value: 0 SEK 2022-01-01 – 2022-12-31: 0 SEK Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Ascelia Pharma · 2022-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Capital Expenditure: 0 SEK Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=SEK&dimensions= Input fundies:CapitalExpenditure: 0 SEK (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2023-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2023-12-31-sv.zip#36316526 Filing: 5493002YR9VCJJPWYN08-2023-12-31-ESEF-SE-0 The citation records this snapshot. The page link may show a newer release later.	−SEK 125.26 million Calculation and evidence -125263000 − 0 SEK Exact free cash flow: -125263000 SEK 2022-01-01 – 2022-12-31: -125263000 SEK · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 0 SEK · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Ascelia Pharma · 2022-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Free cash flow: -125263000 SEK Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -125263000 SEK (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2023-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2023-12-31-sv.zip#36314411 Filing: 5493002YR9VCJJPWYN08-2023-12-31-ESEF-SE-0 Input fundies:CapitalExpenditure: 0 SEK (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2023-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2023-12-31-sv.zip#36316526 Filing: 5493002YR9VCJJPWYN08-2023-12-31-ESEF-SE-0 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−SEK 109.29 million Exact value Exact value: -109288000 SEK 2023-01-01 – 2023-12-31: -109288000 SEK Inspect Net Income Open source Share or cite Citation for Net Income · Ascelia Pharma · 2023-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Net Income: -109288000 SEK Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=SEK&dimensions= Input fundies:NetIncome: -109288000 SEK (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2024-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2024-12-31-0-sv.zip#25781231 Filing: 5493002YR9VCJJPWYN08-2024-12-31-ESEF-SE-0 The citation records this snapshot. The page link may show a newer release later.	−SEK 126.79 million Exact value Exact value: -126792000 SEK 2023-01-01 – 2023-12-31: -126792000 SEK Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Ascelia Pharma · 2023-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Operating Cash Flow: -126792000 SEK Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=SEK&dimensions= Input fundies:OperatingCashFlow: -126792000 SEK (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2024-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2024-12-31-0-sv.zip#25994165 Filing: 5493002YR9VCJJPWYN08-2024-12-31-ESEF-SE-0 The citation records this snapshot. The page link may show a newer release later.	SEK 0 Exact value Exact value: 0 SEK 2023-01-01 – 2023-12-31: 0 SEK Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Ascelia Pharma · 2023-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Capital Expenditure: 0 SEK Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=SEK&dimensions= Input fundies:CapitalExpenditure: 0 SEK (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2024-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2024-12-31-0-sv.zip#25996369 Filing: 5493002YR9VCJJPWYN08-2024-12-31-ESEF-SE-0 The citation records this snapshot. The page link may show a newer release later.	−SEK 126.79 million Calculation and evidence -126792000 − 0 SEK Exact free cash flow: -126792000 SEK 2023-01-01 – 2023-12-31: -126792000 SEK · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 0 SEK · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Ascelia Pharma · 2023-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Free cash flow: -126792000 SEK Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -126792000 SEK (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2024-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2024-12-31-0-sv.zip#25994165 Filing: 5493002YR9VCJJPWYN08-2024-12-31-ESEF-SE-0 Input fundies:CapitalExpenditure: 0 SEK (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2024-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2024-12-31-0-sv.zip#25996369 Filing: 5493002YR9VCJJPWYN08-2024-12-31-ESEF-SE-0 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−SEK 80.03 million Exact value Exact value: -80029000 SEK 2024-01-01 – 2024-12-31: -80029000 SEK Inspect Net Income Open source Share or cite Citation for Net Income · Ascelia Pharma · 2024-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Net Income: -80029000 SEK Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=SEK&dimensions= Input fundies:NetIncome: -80029000 SEK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2024-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2024-12-31-0-sv.zip#25780741 Filing: 5493002YR9VCJJPWYN08-2024-12-31-ESEF-SE-0 The citation records this snapshot. The page link may show a newer release later.	−SEK 62.84 million Exact value Exact value: -62844000 SEK 2024-01-01 – 2024-12-31: -62844000 SEK Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Ascelia Pharma · 2024-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Operating Cash Flow: -62844000 SEK Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=SEK&dimensions= Input fundies:OperatingCashFlow: -62844000 SEK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2024-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2024-12-31-0-sv.zip#25993675 Filing: 5493002YR9VCJJPWYN08-2024-12-31-ESEF-SE-0 The citation records this snapshot. The page link may show a newer release later.	SEK 0 Exact value Exact value: 0 SEK 2024-01-01 – 2024-12-31: 0 SEK Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Ascelia Pharma · 2024-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Capital Expenditure: 0 SEK Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=SEK&dimensions= Input fundies:CapitalExpenditure: 0 SEK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2024-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2024-12-31-0-sv.zip#25995870 Filing: 5493002YR9VCJJPWYN08-2024-12-31-ESEF-SE-0 The citation records this snapshot. The page link may show a newer release later.	−SEK 62.84 million Calculation and evidence -62844000 − 0 SEK Exact free cash flow: -62844000 SEK 2024-01-01 – 2024-12-31: -62844000 SEK · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 0 SEK · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Ascelia Pharma · 2024-12-31 Ascelia Pharma (esef:5493002YR9VCJJPWYN08) Free cash flow: -62844000 SEK Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-12T00:38:49Z Snapshot: 7ecaa998a0e42ec1ae018ef5e268dac5530ae373b14600ad80cd061f2c3d874a Dimensions: Consolidated View: https://fundies.io/companies/esef/5493002YR9VCJJPWYN08?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -62844000 SEK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2024-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2024-12-31-0-sv.zip#25993675 Filing: 5493002YR9VCJJPWYN08-2024-12-31-ESEF-SE-0 Input fundies:CapitalExpenditure: 0 SEK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/5493002YR9VCJJPWYN08/2024-12-31/ESEF/SE/0/5493002YR9VCJJPWYN08-2024-12-31-0-sv.zip#25995870 Filing: 5493002YR9VCJJPWYN08-2024-12-31-ESEF-SE-0 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

4 filings · 306 latest values · 306 originally reported values

Dataset published 2026-11-12. Source filing dates and reporting periods are shown separately.

Identifiers: 5493002YR9VCJJPWYN08, esef:5493002YR9VCJJPWYN08

Ascelia Pharma

Latest fiscal year

Revenue

Operating cash flow

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2024 2024-01-01 – 2024-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation